… Here, we report results of LL8, a phase III trial that prospectively compared A and E in pts …
Here, we report results of LL8, a phase III trial that prospectively compared A and E in pts with …

… PFS was significantly longer with erlotinib than with placebo: 12·3 weeks for patients in the
… grade 3 or higher adverse events were rash (37 [9%] of 443 patients in the erlotinib group vs …

… was the first and largest trial to our knowledge to prospectively investigate erlotinib versus …
in Chinese patients in the OPTIMAL trial. These analyses demonstrate that erlotinib provides a …

… We conducted a phase III study comparing BE to E. Methods: Chemotherapy-naïve pts with
… combination with erlotinib (150 mg daily) plus bevacizumab (15 mg/kg iv q3w) or erlotinib (…

… In this phase III trial, we investigated sunitinib plus erlotinib in patients with advanced NSCLC
who had received one or two prior therapies. The primary end point of this trial, OS, did not …

… wild type tumors, it remains unknown whether E or D is more active against the … III study,
sponsored by the Japanese National Hospital Organization. Patients were randomized to E (150 …

… the sorafenib trials, as 12.5% of patients in this study had Childs… -arm, phase II trials, the
limitations of this study include single … of B + E provides meaningful patient benefit and should be …

… The phase III SATURN study (BO18192) was initiated to evaluate E as … : Patients with no
evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 …

… E improved progression free survival (PFS) in pts with activating EGFR-mutation. We conducted
a multicenter randomized phase III study designed to demonstrate noninferiority of G to E…

… Median TTP: 5.5 months (95% CI 1.9 - 9.2), At time of analysis 22/33 patients are alive, 17
patients are without PD. Conclusions: E + B regimen is well tolerated, with a low rate of grade 3…